In:
Diabetes, American Diabetes Association, Vol. 71, No. Supplement_1 ( 2022-06-01)
Abstract:
Introduction: We evaluated the efficacy and safety of the recommended scheme by international guideline in 2012 (2012’s scheme) in comparison with a less aggressive scheme (2019’s scheme) proposed by Umpierrez et al. Methods: A non-blinded randomized clinical study was conducted in which two short-time insulin schemes for hyperglycemic control (2012’s vs. 2019’s) were compared in hospitalized patients of Hospital Universitario Clínica San Rafael (HUCSR) in Bogotá Colombia in a period between october 2019 and february 2022. Results: Totally, 91 patients joined the trial. There were no statically significant difference between the demographic characteristics and outcomes. Conclusions: The two schemes are equally safe and efficient in our population and can be used interchangeably. Disclosure C. A. Yepes: Speaker’s Bureau; Medtronic, Novo Nordisk, Sanofi. J. M. Mora: None. E. Moscoso: None. J. R. Rodríguez: None. L. A. León: None. J. Gomez: None. N. Buriticá: None.
Type of Medium:
Online Resource
ISSN:
0012-1797
Language:
English
Publisher:
American Diabetes Association
Publication Date:
2022
detail.hit.zdb_id:
80085-5